-
Canaccord Genuity Reiterates Buy Rating on Biodesix (BDSX)
-
Biodesix Inc. (BDSX) Misses Q3 EPS by 110c
-
Biodesix (BDSX) PT Lowered to $20 at Canaccord Genuity
-
Biodesix Inc. (BDSX) Misses Q2 EPS by 1c ; Offers Guidance
-
Biodesix (BDSX) PT Lowered to $2 at Scotiabank
-
Biodesix Inc. (BDSX) Misses Q1 EPS by 1c ; Offers Guidance
-
Biodesix (BDSX) PT Lowered to $2 at TD Cowen; '1Q Miss & Guide Down as Sales Force Headcount Lags'
-
William Blair Downgrades Biodesix (BDSX) to Market Perform
-
Biodesix (BDSX) PT Lowered to $1.50 at Canaccord Genuity
-
Biodesix Inc. (BDSX) Tops Q4 EPS by 1c
-
Biodesix Inc. (BDSX) Reports In-Line Q3 EPS
-
Biodesix Inc. (BDSX) Tops Q2 EPS by 1c ; Offers Guidance
-
Craig-Hallum Starts Biodesix (BDSX) at Buy

